Clinical Trial Update: A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 [Phase 1]

View source ↗

Summary

Luye Pharma Group is conducting a Phase 1 multiple ascending dose study to assess the safety and tolerability of LY03020. The trial targets schizophrenia and Al…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease with Psychosis
• Schizophrenia

Drugs mentioned

• LY03020

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Schizophrenia, Alzheimer's Disease Psychosis | Phase 1 | Status: RECRUITING